Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)
Funding Opportunity PA-19-201 from the NIH Guide for Grants and Contracts. The purpose of this FOAs are to encourage mechanistic research to investigate the impact of sleep disturbances on chronic pain. The mechanisms and processes underlying the contribution of sleep disturbances to chronic pain development and maintenance may be very broad. This FOA encourages interdisciplinary collaborations by experts from multiple fieldsneuroscientists, psychologists,endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of in...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 28, 2019 Category: Research Source Type: funding
Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)
Funding Opportunity PA-19-200 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fieldsneuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 28, 2019 Category: Research Source Type: funding
Welcome the New Director for the NIH Center for Scientific Review – Dr. Noni Byrnes
It gives me
enormous pleasure to extend my warm congratulations to a friend and colleague, Noni H. Byrnes, Ph.D., for her recent selection as the
new Director for the NIH Center for Scientific Review (CSR).
CSR serves a
vital role. Not only does CSR manage the receipt and referral of all grant applications
for NIH and for other parts of the U.S. Department of Health and Human Services,
dedicated CSR staff also oversee the peer review of approximately 75 percent of
the more than 80,000 grant applications NIH receives each year. One can find
more data on NIH peer review “in” the NIH Data Book.
A...
Source: NIH Extramural Nexus - February 21, 2019 Category: Research Authors: Mike Lauer Tags: Open Mike CSR Peer review Source Type: funding
NSF/CASIS Collaboration on Transport Phenomena Research on the International Space Station (ISS) to Benefit Life on Earth
Full Proposal Window: March 15, 2019 Program Guidelines: NSF 19-525The Division of Chemical, Bioengineering and Environmental Transport (CBET) in the Engineering Directorate of the National Science Foundation (NSF) is partnering with The Center for the Advancement of Science in Space (CASIS) to solicit research projects in the general field of fluid ...More at https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505258&WT.mc_id=USNSF_39&WT.mc_ev=clickThis is an NSF Upcoming Due Dates item. (Source: NSF Upcoming Due Dates)
Source: NSF Upcoming Due Dates - February 13, 2019 Category: Science Source Type: funding
Functional RNA Modifications Environment and Disease (FRAMED) (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-19-001 from the NIH Guide for Grants and Contracts. Chemical modifications of protein, DNA and RNA nucleoside moieties play critical roles in regulating gene expression. Emerging evidence suggests RNA modifications have substantive roles in multiple basic biological processes. Epitranscriptomics can be defined as the aggregate suite of functional biochemical modifications to the transcriptome within a cell. Recent studies in yeast, Drosophila, rodent and human models demonstrate that stressors can induce RNA modifications, with specific reprogramming of some regulatory RNAs. The NIEHS seeks to...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 8, 2019 Category: Research Source Type: funding
Functional RNA Modifications Environment and Disease (FRAMED) (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-19-002 from the NIH Guide for Grants and Contracts. Chemical modifications of proteins, DNA and RNA nucleoside moieties play critical roles in regulating gene expression. Emerging evidence suggests these RNA modifications (epitranscriptomics) have substantive roles in basic biological processes. Recent studies in yeast, Drosophila and rodent models demonstrate stressors can induce RNA modifications, with specific epitranscriptomic reprogramming of some regulatory RNAs. The purpose of the eFRAMED FOA is to solicit and support R21 applications that propose conducting innovative, high risk, high ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 8, 2019 Category: Research Source Type: funding
Dear Colleague Letter: Division of Chemistry (CHE) International Supplements 2019
Available Formats: HTML: https://www.nsf.gov/pubs/2019/nsf19037/nsf19037.jsp?WT.mc_id=USNSF_25&WT.mc_ev=clickPDF: https://www.nsf.gov/pubs/2019/nsf19037/nsf19037.pdf?WT.mc_id=USNSF_25&WT.mc_ev=clickDocument Number: nsf19037This is an NSF Program Announcements and Information item. (Source: NSF Program Announcements and Information)
Source: NSF Program Announcements and Information - February 8, 2019 Category: Science Source Type: funding
NSF/CASIS Collaboration on Tissue Engineering and Mechanobiology on the International Space Station (ISS) to Benefit Life on Earth
Full Proposal Window: February 15, 2019 Program Guidelines: NSF 19-509The Divisions of Chemical, Bioengineering and Environmental Transport (CBET) and Civil, Mechanical, and Manufacturing Infrastructure (CMMI) in the Engineering Directorate of the National Science Foundation (NSF) are partnering with The Center for the Advancement of Science in Space (CASIS) to solicit research projects in the general fields of tissue engineering and mechanobiology that can utilize the International Space Station (ISS) National Lab to conduct research that will benefit life on ...More at https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505...
Source: NSF Upcoming Due Dates - January 26, 2019 Category: Science Source Type: funding
Center for Natural Product Technology, Methodology, and Productivity Optimization (NP-TEMPO) (U41 Clinical Trial Not Allowed)
Funding Opportunity RFA-AT-19-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to establish a National Center for Natural Product Technology Methodology and Performance Optimization (NP-TEMPO). This initiative is to improve upon and strengthen technologies and methods used in natural products research. The NP-TEMPO, supported through the U41 cooperative agreement funding mechanism, is expected to overcome existing research limitations by developing and/or adapting cutting edge, innovative approaches and technologies that will have sign...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 22, 2019 Category: Research Source Type: funding
Natural Products NMR Open Data Exchange (NP-NODE) (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-AT-19-002 from the NIH Guide for Grants and Contracts. The National Center for Complementary and Integrative Health (NCCIH) with the Office of Dietary Supplements (ODS) solicit applications for the development of an NMR Open Data Exchange (NP-NODE) and associated efforts to accelerate coordination and data sharing among natural products researchers more broadly. The NP-NODE will create the resources necessary to facilitate the capacity to upload, download, store, search and analyze raw NMR data. This resource will comply with the principle that scientific data should be Findable, Accessible, Inte...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 22, 2019 Category: Research Source Type: funding
Drug Discovery For Nervous System Disorders (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-146 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIH wishes to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics, and 4) Initial...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 8, 2019 Category: Research Source Type: funding
Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
Funding Opportunity PAR-19-147 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 8, 2019 Category: Research Source Type: funding
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-009 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R01 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-008 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding
Resources for Technology Dissemination (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-EB-18-002 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support non-commercial lab-to-user dissemination of novel, reliable imaging and bioengineering technologies, including devices, software, methods, chemical agents, etc. Proposed technologies should have been prototyped, validated, and are potentially highly impactful to the research community. However, their beyond-the-lab dissemination via commercialization or industry partnership is not anticipated. Projects should focus on transforming functioning prototypes to usable tools a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 26, 2018 Category: Research Source Type: funding
